{
  "id": 16021738,
  "title": "Why is Tubize-Fin stock surging today?",
  "url": "https://urgent.news/2026/10/22/why-is-tubize-fin-stock-surging-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-22T08:51:13.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-tubizefin-stock-surging-today-93CH-4965044"
  },
  "original_language": "en",
  "account": "Tubize-Fin stock experienced a significant surge of 9.3% on the day after UCB, the Belgian biopharmaceutical company that owns Tubize-Fin entirely, issued an upgraded financial guidance for the year 2026. UCB now anticipates adjusted EBITDA growth in the low to mid forties percentage range at constant exchange rates, a substantial jump from their previous forecast of 10-20% growth. They also expect revenue growth of around 20%, driven by the successful market entry of their IL-17A/F inhibitor, Bimzelx, in the United States. The upgrade was based on UCB's faster patient conversion, higher retention rates, and improved channel mix for Bimzelx, along with improved volume growth and net pricing for their existing drug, Cimzia. As Tubize-Fin is a pure holding company with a 36% stake in UCB, any significant change in UCB's earnings value directly impacts Tubize-Fin's intrinsic value. Therefore, this positive update on UCB's outlook led to a logical and expected re-rating of Tubize-Fin's stock. On a broader scale, the BEL 20 index, Belgium's benchmark, barely moved the previous day, and U.S. equity markets are currently trading lower, indicating that Tubize-Fin's sharp increase is solely due to the UCB-specific catalyst rather than any macroeconomic factors. Tubize-Fin opened at €187, peaked at €204.4 during the session, and is currently trading at €197.1, above its 52-week low of €168.1 but still below its 52-week high of €250.5. This sharp rise in Tubize-Fin's stock is a direct result of UCB's substantial guidance upgrade reflecting the commercial maturity of Bimzelx as a multi-billion-euro franchise. With the stock trading at a substantial discount to analyst consensus price targets, today's catalyst has reinvigorated investor interest in Tubize-Fin's long-term value proposition.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}